Terms: = Brain cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
53 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.
Le Hars M; Castro-Vega LJ; Rajabi F; Tabatadze D; Romero M; Pinskaya M; Groisman I
Biol Direct; 2023 Jul; 18(1):38. PubMed ID: 37434219
[TBL] [Abstract] [Full Text] [Related]
3. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract] [Full Text] [Related]
4. Integrative clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease.
Moreno-Moreno P; Ibáñez-Costa A; Venegas-Moreno E; Fuentes-Fayos AC; Alhambra-Expósito MR; Fajardo-Montañana C; García-Martínez A; Dios E; Vázquez-Borrego MC; Remón-Ruiz P; Cámara R; Lamas C; Carlos Padillo-Cuenca J; Solivera J; Cano DA; Gahete MD; Herrera-Martínez AD; Picó A; Soto-Moreno A; Gálvez-Moreno MÁ; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2938-e2951. PubMed ID: 35312002
[TBL] [Abstract] [Full Text] [Related]
5. Radiation induced contrast enhancement after proton beam therapy in patients with low grade glioma - How safe are protons?
Harrabi SB; von Nettelbladt B; Gudden C; Adeberg S; Seidensaal K; Bauer J; Bahn E; Mairani A; Alber M; Haberer T; Debus J; Herfarth K
Radiother Oncol; 2022 Feb; 167():211-218. PubMed ID: 34973277
[TBL] [Abstract] [Full Text] [Related]
6. Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
Feng W; Chen X; Guan SX; Ruan HL; Huang Y; Zhang HZ; Yang YP; Fang WF; Zhao HY; Zhuang W; Xin S; Chen YH; Wang F; Gao Y; Huang M; Wang XD; Zhang L
Acta Pharmacol Sin; 2022 Jul; 43(7):1857-1864. PubMed ID: 34737420
[TBL] [Abstract] [Full Text] [Related]
7. clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
Ahn BC; So JW; Synn CB; Kim TH; Kim JH; Byeon Y; Kim YS; Heo SG; Yang SD; Yun MR; Lim S; Choi SJ; Lee W; Kim DK; Lee EJ; Lee S; Lee DJ; Kim CG; Lim SM; Hong MH; Cho BC; Pyo KH; Kim HR
Eur J Cancer; 2021 Aug; 153():179-189. PubMed ID: 34182269
[TBL] [Abstract] [Full Text] [Related]
8.
Li J; Zhang Q; Ge P; Zeng C; Lin F; Wang W; Zhao J
Dis Markers; 2020; 2020():8888085. PubMed ID: 33299501
[TBL] [Abstract] [Full Text] [Related]
9. Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Gao G; Yang M; Wang F; Dang G; Zhang X; Zhao J; Wang X; Jin B
Aging (Albany NY); 2020 Jun; 12(11):10594—10613. PubMed ID: 32507767
[TBL] [Abstract] [Full Text] [Related]
10. Radiomics: A primer for the radiation oncologist.
Bibault JE; Xing L; Giraud P; El Ayachy R; Giraud N; Decazes P; Burgun A; Giraud P
Cancer Radiother; 2020 Aug; 24(5):403-410. PubMed ID: 32265157
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas.
Song LR; Weng JC; Li CB; Huo XL; Li H; Hao SY; Wu Z; Wang L; Li D; Zhang JT
JCI Insight; 2020 Mar; 5(8):. PubMed ID: 32229719
[TBL] [Abstract] [Full Text] [Related]
12. cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma.
Fathi Kazerooni A; Akbari H; Shukla G; Badve C; Rudie JD; Sako C; Rathore S; Bakas S; Pati S; Singh A; Bergman M; Ha SM; Kontos D; Nasrallah M; Bagley SJ; Lustig RA; O'Rourke DM; Sloan AE; Barnholtz-Sloan JS; Mohan S; Bilello M; Davatzikos C
JCO Clin Cancer Inform; 2020 Mar; 4():234-244. PubMed ID: 32191542
[TBL] [Abstract] [Full Text] [Related]
13. The Role of mPRδ and mPRε in Human Glioblastoma Cells: Expression, Hormonal Regulation, and Possible clinical outcome.
Del Moral-Morales A; González-Orozco JC; Capetillo-Velázquez JM; Piña-Medina AG; Camacho-Arroyo I
Horm Cancer; 2020 Apr; 11(2):117-127. PubMed ID: 32077034
[TBL] [Abstract] [Full Text] [Related]
14. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong TS; Dirven L; Arons D; Bates A; Chang SM; Coens C; Espinasse C; Gilbert MR; Jenkinson D; Kluetz P; Mendoza T; Rubinstein L; Sul J; Weller M; Wen PY; van den Bent MJ; Taphoorn MJB
Lancet Oncol; 2020 Feb; 21(2):e97-e103. PubMed ID: 32007210
[TBL] [Abstract] [Full Text] [Related]
15. Overview of DNA methylation in adult diffuse gliomas.
Aoki K; Natsume A
Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
[TBL] [Abstract] [Full Text] [Related]
16. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
[TBL] [Abstract] [Full Text] [Related]
17. Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism.
Wu M; Miska J; Xiao T; Zhang P; Kane JR; Balyasnikova IV; Chandler JP; Horbinski CM; Lesniak MS
J Neurooncol; 2019 Apr; 142(2):375-384. PubMed ID: 30706176
[TBL] [Abstract] [Full Text] [Related]
18. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy.
Wang PG; Li YT; Pan Y; Gao ZZ; Guan XW; Jia L; Liu FT
J Neurooncol; 2019 Jan; 141(1):71-81. PubMed ID: 30446901
[TBL] [Abstract] [Full Text] [Related]
19. Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma.
Liu YQ; Chai RC; Wang YZ; Wang Z; Liu X; Wu F; Jiang T
Cancer Sci; 2019 Jan; 110(1):321-333. PubMed ID: 30431206
[TBL] [Abstract] [Full Text] [Related]
20. Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report.
Kaur E; Goda JS; Ghorai A; Salunkhe S; Shetty P; Moiyadi AV; Sridhar E; Mahajan A; Jalali R; Dutt S
Cell Oncol (Dordr); 2019 Feb; 42(1):107-116. PubMed ID: 30361826
[TBL] [Abstract] [Full Text] [Related]
[Next]
